2-Amino-4-ethyl-1,3-thiazole-5-carboxylic acid | 191105-37-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Amino-4-ethyl-1,3-thiazole-5-carboxylic acid
• CAS: 191105-37-0
• 化学式: C₆H₈N₂O₂S
• mdl: MFCD13188627
• 分子量: 172.21
• InChiKey: OHUPJQLYQCVDHP-UHFFFAOYSA-N

物化性质

• 沸点：
  377.7±22.0 °C(Predicted)
• 密度：
  1.437±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Cyclic protein tyrosine kinase inhibitors
  申请人：——

  公开号：US20040054186A1

  公开（公告）日：2004-03-18

  Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

  新型环状化合物及其盐类，含有此类化合物的药物组合物，以及使用此类化合物治疗蛋白质酪氨酸激酶相关疾病，如免疫和肿瘤疾病的方法。
• [EN] CYCLIC PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS CYCLIQUES DE PROTEINE TYROSINE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2000062778A1

  公开（公告）日：2000-10-26

  Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

  小说环状化合物及其盐，含有这些化合物的制药组合物，以及使用这些化合物治疗蛋白酪氨酸激酶相关疾病（如免疫和肿瘤疾病）的方法。
• CYCLIC PROTEIN TYROSINE KINASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20140206691A1

  公开（公告）日：2014-07-24

  Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

  新型环状化合物及其盐，含有这种化合物的药物组合物，以及使用这种化合物治疗蛋白酪氨酸激酶相关疾病（如免疫和肿瘤疾病）的方法。
• Compounds Effecting Glucokinase
  申请人：Boyd Scott

  公开号：US20080207636A1

  公开（公告）日：2008-08-28

  The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

  本发明涉及使用化合物式(I)或其盐、溶剂化物或前药，其中R1、R2、R3、n和m如规范所述，在制备治疗或预防通过葡萄糖激酶（GLK）介导的疾病状态，如2型糖尿病的药物。本发明还涉及一类新的化合物式(I)和制备化合物式(I)的方法。
• Cyclopropyl derivative lipoxygenase inhibitors
  申请人：ABBOTT LABORATORIES

  公开号：EP0436199A1

  公开（公告）日：1991-07-10

  Certain carbocyclic aryl- and heterocyclic aryl- substituted cyclopropyl N-hydroxyureas, N-hydroxy-carboxamides, and N-acyl-N-hydroxyamines inhibit 5- and/or 12-lipoxygenase and are useful in the treatment of inflammatory disease states.

  某些碳环芳基和杂环芳基取代的环丙基 N-羟基脲、N-羟基羧酰胺和 N-酰基-N-羟基胺可抑制 5-和/或 12-脂氧合酶，可用于治疗炎症性疾病。